Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma
Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma
复制标题
DOI:
10.1016/j.ejca.2017.08.026
复制
发表时间:
2017-11-01
影响因子:
8.4
通讯作者:
Kawakami, Yutaka
中科院分区:
文献类型:
--
作者:
Kinoshita, Tomonari;Kudo-Saito, Chie;Kawakami, Yutaka
We have previously demonstrated that the prognostic significance of tumour-infiltrating CD8(+) T cells significantly differs according to histological type and patient smoking habits in non-small cell lung cancer (NSCLC). This work suggested that infiltrating CD8(+) T cells may not be activated sufficiently in the immunosuppressive microenvironment in non-smokers with adenocarcinoma. To understand the immunogenic microenvironment in NSCLC, we characterised immune cells comprehensively by performing an immunohistochemical evaluation using an alternative counting method and multicolour staining method (n = 234), and assessed immune-related gene expression by using genetic analytical approaches (n = 58). We found that high infiltration of activated CD8(+) T cells expressing interferon gamma (IFN-gamma) and granzyme was correlated with postoperative survival in patients with non-adenocarcinoma. On the contrary, CD8(+) T-cell accumulation was identified as a worse prognostic factor in patients with adenocarcinoma, particularly in non-smokers. Infiltrating CD8(+) T cells were significantly less activated in this microenvironment with high expression of various immunoregulation genes. Potentially immunoregulatory CD8(+) FOXP3(+) T cells and immunodysfunctional CD8(+) GATA3(+) T cells were increased in adenocarcinoma of non-smokers. CD8(+) FOXP3(+) regulatory T cells expressing chemokine receptor-4 (CCR4)-and chemokine ligand (CCL17)-expressing CD163(+) M2-like macrophages also accumulated correlatively and significantly in adenocarcinoma of non-smokers. These characteristic immune cells may promote tumour progression possibly by creating an immunosuppressive microenvironment in non-smoking patients with lung adenocarcinoma. Our findings may be helpful for refining the current strategy of personalised immunotherapy including immune-checkpoint blockade therapy for NSCLC. (C) 2017 Elsevier Ltd. All rights reserved.